SCHEMBL652674

SCHEMBL652674

NC(CO)Cc1ccc(Cl)cc1

nearest known ligand 0.78

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.78
SLC6A2 P23975 1/20 0.59
SLC6A3 Q01959 1/20 0.59
DPP4 P27487 1/20 0.45
DPP7 Q9UHL4 1/20 0.45
EPHX1 P07099 1/20 0.44
NMT1 P30419 2/20 0.43
TAAR1 Q96RJ0 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
IDO1 P14902 4/20 0.41
AGXT P21549 2/20 0.41
ANPEP P15144 2/20 0.40
ENPEP Q07075 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779366 1.00 SLC6A4 (0.78) SLC6A4SLC6A2SLC6A3DPP4DPP7
SCHEMBL7957756 1.00 SLC6A4 (0.78) SLC6A4SLC6A2SLC6A3DPP4DPP7
SCHEMBL2295017 0.89 SLC6A4 (0.62) SLC6A4SLC6A2SLC6A3NMT1PPARG
SCHEMBL2295009 0.89 SLC6A4 (0.62) SLC6A4SLC6A2SLC6A3NMT1PPARG
Hydrochloric Acid SCHEMBL6478645 0.87 SLC6A4 (0.60) SLC6A4SLC6A2SLC6A3PPARGPPARA
Hydrochloric Acid SCHEMBL6478641 0.87 SLC6A4 (0.60) SLC6A4SLC6A2SLC6A3PPARGPPARA
Trifluoroacetic Acid SCHEMBL4544157 0.86 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3DPP4DPP7
SCHEMBL9921946 0.82 SLC6A4 (0.78) SLC6A4SLC6A2SLC6A3DPP4DPP7
SCHEMBL3441646 0.82 SLC6A4 (0.78) SLC6A4SLC6A2SLC6A3DPP4DPP7
SCHEMBL18607979 0.81 SLC6A4 (0.69) SLC6A4SLC6A2SLC6A3DPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106458866-A Aminocarbonyl carbamate compound 爱思开生物制药株式会社 2017-02-22 CN claimed
EP-2414346-B1 AUTOTAXIN INHIBITORS MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-8497283-B2 Autotaxin inhibitors MERCK PATENT GMBH (DE) 2013-07-30 US claimed
US-20130023556-A1 AUTOTAXIN INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-01-24 US claimed
US-8329907-B2 Autotaxin inhibitors MERCK PATENT GMBH (DE) 2012-12-11 US claimed
WO-2010112124-A1 AUTOTAXIN INHIBITORS MERCK PATENT GMBH (DE) 2010-10-07 WO claimed
EP-1653961-A4 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORP (US) 2009-04-01 EP claimed
US-20080255143-A1 Inhibitors of Akt Activity SMITHKLINE BEECHAM CORPORATION (PA) 2008-10-16 US claimed
CN-1859912-A Inhibitors of Akt activity SMITHKLINE BEECHAM CORP (US) 2006-11-08 CN claimed
EP-1653961-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 EP claimed
WO-2005011700-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-02-10 WO claimed
US-12325701-B2 YKL-40 inhibitors and their therapeutic MOLECURE S.A. (PL) 2025-06-10 US disclosed
EP-4269400-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS Molecure SA (PL) 2023-11-01 EP disclosed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US disclosed
CN-114057714-B Heterocyclyl-substituted aminotriazole derivatives and their use 苏州健雄职业技术学院 2023-07-14 CN disclosed
WO-2001009127-A1 BENZOXAZINE DERIVATIVES AND THEIR THERAPEUTIC USE AVENTIS PHARMA S.A. (FR) 2001-02-08 WO disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 WO disclosed
US-5466687-A Anticholesterol agents DR. KARL THOMAE GMBH (DE) 1995-11-14 US disclosed
EP-0596326-B1 Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production THOMAE GMBH DR K (DE) 1995-08-23 EP disclosed
EP-0596326-A1 Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production Dr. Karl Thomae GmbH (DE) 1994-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA SLC6A4 4256/4885SLC6A2 4802/4885SLC6A3 4775/4885
US-20080255143-A1 Inhibitors of Akt Activity PI4KB, PIK3CA, AKT2 SLC6A4 4637/4885SLC6A2 4822/4885SLC6A3 4780/4885
US-12325701-B2 YKL-40 inhibitors and their therapeutic CHI3L1, CHI3L2, CHIA SLC6A4 4021/4885SLC6A2 4753/4885SLC6A3 4725/4885
US-20130023556-A1 AUTOTAXIN INHIBITORS ENPP2, PLA2G12A, LPCAT1 SLC6A4 4135/4885SLC6A2 3711/4885SLC6A3 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.